TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An autopsy study of 230 people with Parkinson’s disease found higher rates of Alzheimer’s amyloid pathology in women, particularly women with Parkinson’s disease dementia. Researchers found no sex difference in tau pathology or cognitive impairment, and the results do not establish whether amyloid-targeting drugs would help people with Parkinson’s.
Women in an autopsy study of people with Parkinson’s disease had higher rates of Alzheimer’s-related amyloid pathology than men, with the difference particularly apparent among women who had Parkinson’s disease dementia, researchers reported in the Journal of Parkinson’s Disease. The study examined 230 cases; it did not find sex differences in tau pathology or levels of cognitive impairment.
The researchers analyzed autopsy cases drawn from the Arizona Study of Aging and Neurodegenerative Disorders and the Brain and Body Donation Program. They compared brain pathology in women and men who had Parkinson’s disease, looking for signs associated with Alzheimer’s as well as Parkinson’s.
The main difference reported was in amyloid pathology, which involves the buildup of amyloid protein into plaques and is associated with Alzheimer’s disease. The study’s title describes a greater burden of Alzheimer’s co-pathology in women with Parkinson’s disease dementia. The report does not provide a percentage or other numerical estimate for the difference.
Researchers reported no detected sex difference in tau pathology, another type of brain change associated with Alzheimer’s, or in levels of cognitive impairment. The findings concern pathology identified in donated brains after death; they do not show that women with Parkinson’s are more likely to develop dementia in life, or that amyloid caused dementia in the participants.
Why Amyloid Findings Matter
The results add evidence that Parkinson’s and Alzheimer’s-related changes can occur in the same brain, and suggest that the pattern of this overlap may differ by sex. That may help researchers refine how they study cognitive decline among people with Parkinson’s, rather than treating every case of dementia as having the same underlying biology.
The finding may also guide future treatment research. Anti-amyloid medicines are approved for certain people diagnosed with Alzheimer’s, and lead researcher Erika Driver-Dunckley said the results raise the possibility of studying whether such treatments could benefit a subset of people with Parkinson’s disease dementia who also have increased amyloid pathology. That is a research question, not evidence that these medicines work for Parkinson’s dementia. The study did not test a treatment or establish clinical benefit.
For patients and families, the distinction matters: the results do not change current care recommendations or provide a way to predict an individual’s pathology from sex alone. They point instead to a possible difference in the biology found across groups that warrants further study.
Products Worth Considering
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
Therabody SleepMask with Vibration
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
As an affiliate, we earn on qualifying purchases.
Mixed Brain Pathology in Parkinson’s
People diagnosed with one neurodegenerative condition can have signs of other diseases in the brain. Driver-Dunckley said this is often recognized through autopsy studies, where researchers can examine brain tissue directly and identify multiple pathologies that may not have been apparent from the person’s original diagnosis.
In this study, the notable observation was not simply that Alzheimer’s-related changes appeared alongside Parkinson’s. The researchers said the sex difference in amyloid pathology was what drew their attention. The work was conducted through AZSAND and the Brain and Body Donation Program and was published as “Greater burden of Alzheimer’s Co-pathology in women with Parkinson’s disease dementia” in the journal’s 2026 volume.
Because the analysis used autopsy cases, it offers a direct view of brain pathology but cannot by itself establish when the changes began, how they affected symptoms over time, or whether one pathology contributed to another. Those questions require evidence beyond a comparison of donated brains.
“In women, particularly those with Parkinson’s disease dementia, they had higher rates of Alzheimer’s amyloid pathology.”
— Erika Driver-Dunckley, M.D., Mayo Clinic movement disorder neurologist and a lead researcher
Limits of the Autopsy Evidence
The report does not state the size of the difference in amyloid pathology, the participants’ demographic breakdown, or how representative the 230 donated cases are of all people living with Parkinson’s. Without those details, the finding should not be treated as a population-wide estimate of risk.
Autopsy evidence also cannot establish whether amyloid changes contributed to dementia, developed alongside other changes, or were associated with other factors. The study found no sex difference in cognitive impairment, but it does not explain why the pathology difference appeared or whether it affects symptoms during life. It remains unknown whether people with Parkinson’s and elevated amyloid would respond to Alzheimer’s anti-amyloid medicines; the study did not evaluate those drugs.
Testing Amyloid Treatment Questions
The next step is further research to determine whether the reported pattern holds in other groups and how amyloid pathology relates to symptoms over time in people with Parkinson’s. Studies that follow participants during life and assess both biomarkers and cognition could help clarify whether the autopsy finding has practical relevance for diagnosis or treatment research.
Driver-Dunckley’s comments point to a possible future question: whether selected patients with Parkinson’s disease dementia and increased amyloid pathology might benefit from anti-amyloid treatment. That would require studies designed to assess safety and effectiveness in this specific population. No such benefit was demonstrated by the 230-case autopsy analysis, and no treatment recommendation follows from it.
Key Questions
What did the study find?
In an autopsy series of 230 people with Parkinson’s disease, researchers reported higher rates of Alzheimer’s amyloid pathology in women, especially among women with Parkinson’s disease dementia.
Did women also have more tau pathology?
No sex difference in tau pathology was reported. Researchers also found no difference between women and men in levels of cognitive impairment.
Does this mean women with Parkinson’s are more likely to develop dementia?
The study does not establish that. It examined brain pathology in autopsy cases and reported an amyloid difference; it does not show that women with Parkinson’s are more likely to develop dementia during life.
Could Alzheimer’s drugs help people with Parkinson’s dementia?
The study did not test Alzheimer’s medicines. Researchers said the finding could support future research into anti-amyloid drugs for selected patients, but whether they would help remains unknown.
Source: news-medical.net
